



Hepatitis Vaccines

José Romero, MD, FAAP, FIDSA, FPIDS
Chair, Hepatitis Vaccines Work Group

Advisory Committee on Immunization Practices
February 21, 2018

ACIP Hepatitis WG Terms of Reference

Hepatitis A

- Update hepatitis A recommendations
 - ACIP Routine Recommendation for Hepatitis A Vaccine, MMWR 2006 May 19;55(RR-7):1-23
- Use of Hepatitis A vaccine for post-exposure prophylaxis among adults >40 years
 - Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the ACIP, MMWR 2007 Oct 19;56(41):1080-4

Hepatitis B

- New ACIP recommendations for HEPLISAV-B
 - FDA licensed November 9, 2017
- [Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR 2018 Jan 12;67(RR-1):1-31]

Work Group Considerations

▪ November 2017 – February 2018

Hepatitis A

- Risk factors for hepatitis A virus infection: HIV and immunocompromised
- Review of homeless as a risk group discussion
- Review of hepatitis A virus post-exposure prophylaxis and international travel draft policy statement

Hepatitis B

- HEPLISAV-B GRADE
- HEPLISAV-B considerations and proposed recommendations
- Draft policy note: Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

Today's Session

Hepatitis B

- HEPLISAV-B GRADE
- HEPLISAV-B considerations and proposed recommendations
- **Vote**

Hepatitis A

- Hepatitis A post-exposure prophylaxis GRADE
- Hepatitis A post-exposure prophylaxis and international travel considerations and proposed recommendations
- **Vote**

Next Steps

- **Present the full updated hepatitis A vaccine statement for vote**
- **Continue deliberations on adult hepatitis B vaccination**

Hepatitis Work Group Members

ACIP Members

José Romero (Chair)
Echezona Ezeanolue
Sharon Frey
Kelly Moore

Liaison Representatives

Natali Aziz (ACOG)
Elizabeth Barnett (AAP)
Susan Even (ACHA)
Christine Finley (AIM)
Susan Lett (CSTE)
Gregory Poland (ACP)
Pamela Rockwell (AAFP)
David Weber (SHEA)
Matthew Zahn (NACCHO)

Ex Officio Member

Marian Major (FDA)

Consultants

Sharon Balter (LA-DPH)
Robert Frenck (CCHMC)
Kathleen Harriman (CDPH)
Brian McMahon (ANTHC)
David Nace (AMDA)
Arthur Reingold (UC Berkeley)
Jennifer Rosen (NYC-DOH)
Ann Thomas (OR-DHS/OHA)
Jennifer Zipprich (CDPH)

Lead

Noele Nelson
(CDC/Viral Hepatitis Division)

Acknowledgements

- **NCHHSTP/Division of Viral Hepatitis**

- Mona Doshani
- Megan Hofmeister
- Alaya Koneru
- John Ward

- **NCIRD/Immunization Services Division**

- **ACIP Hepatitis Work Group**

- Maria Cano
- Melissa Collier
- Kristina Angelo
- Penina Haber
- Aaron Harris
- Beth Hibbs
- Scott Holmberg
- Ruth Jiles
- Andrew Kroger
- Ruth Link-Gelles
- David Kim
- Tina Objio
- Sarah Schillie
- Brenna Simons-Petrusa
- Phil Spradling
- Tureka Watson
- Matthew Wise

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

